Migraine Epidemiology Forecast

DelveInsight’s ‘Migraine— Epidemiology Forecast to 2032’ report delivers an in-depth understanding of the Migraine, historical and forecasted epidemiology in the United States, the EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • The EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019–2032

Migraine-Disease Understanding

Migraine is ranked globally as the seventh most disabling disease among all diseases (responsible for 2.9% of all years of life lost to disability/YLDs) and the leading cause of disability among all neurological disorders.

 

It includes severe throbbing recurring pain, usually on one side of the head, often accompanied by visual disturbances, nausea, vomiting, dizziness, extreme sensitivity to sound, light, touch and smell, and tingling or numbness in the extremities or face; although symptoms usually include a severe throbbing recurring pain on one side of the head, yet in one-third of migraine attacks, both sides are found to be affected.

 

Migraine is classified by the nature of the attack and its frequency as chronic and episodic migraine. Episodic migraine is characterized by those with migraine who have 0–14 headache days per month, while chronic migraine is characterized by 15 or more headache days per month.

 

Migraine remains undiagnosed and undertreated in at least ~ 50% of patients, and less than 50% of migraine patients consult a physician.

 

Treatment can be acute or preventive. Acute treatment is initiated during an attack to alleviate pain and disability and to stop the progression of the attack. Preventive treatment is used when there exists a known headache trigger, such as exercise or sexual activity, and for patients who have limited time exposure to a trigger, such as high-altitude ascent or menstruation.

 

The overall dynamics of the Migraine market is anticipated to change in the coming years owing to the expected launch of emerging therapies and others are developing treatments for Migraine.

Migraine Epidemiology

The Migraine epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for the seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

 

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Migraine epidemiology segmented as Total Prevalence of Migraine, Prevalent Cases of Migraine based on severity, Gender specific Prevalence of Migraine, and Diagnosed Cases of Chronic and Episodic Migraine. The report includes the prevalent scenario of Migraine in the 7MM covering the United States, the EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise-Chronic Migraine Epidemiology

The epidemiology segment also provides the Migraine epidemiology data and findings across the United States, the EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

  • The total prevalent population of Migraine associated in the 7MM countries was estimated to be 118,491,327 cases in 2021 and expected to increase at a CAGR of 0.32% for the study period, i.e., 2019–2032.
  • As per the estimates, United States has the highest prevalence population of Migraine in the 7MM.
  • Among the EU5 countries, Germany had the highest prevalent population of Migraine. On the other hand Spain reported the lowest prevalent population. In 7MM, Spain had the lowest number of cases i.e. 9,314,356 cases in 2021.

Scope of the Report

  • Migraine report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns
  • Migraine Epidemiology Report and Model provides an overview of the risk factors and global trends of Migraine in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight into the historical and forecasted patient pool of Migraine in the seven major markets covering the United States, the EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps recognize the growth opportunities in the 7MM concerning the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Migraine
  • The report provides the segmentation of the Migraine epidemiology by Total Prevalence of Migraine in the 7MM
  • The report provides the segmentation of the Total Prevalence of Migraine, Prevalent Cases of Migraine based on severity, Gender specific Prevalence of Migraine, and Diagnosed Cases of Chronic and Episodic Migraine  in the 7MM

Report Highlights

  • 11-year Forecast of Migraine epidemiology
  • 7MM Coverage
  • Total Prevalent cases of Migraine
  • Gender-specific Cases of Migraine
  • Diagnosed Cases of Chronic and Episodic Migraine 

KOL Views

We interview KOLs, and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM concerning the patient population about Migraine?
  • What are the Key Findings of Migraine epidemiology across the 7MM, and which country will have the highest number of patients during the forecast period (2022–2032)?
  • What would be the total number of patients with Migraine across the 7MM during the forecast period (2022–2032)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2022–2032)?
  • At what CAGR the patient population is expected to grow by 7MM during the forecast period (2022–2032)?
  • What are the disease risk, burden, and unmet needs of Migraine?
  • What are the currently available treatments for Migraine?

Reasons to buy

The Migraine Epidemiology report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global Migraine market
  • Quantify patient populations in the global Migraine market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and gender that present the best opportunities for Migraine therapeutics in each of the markets covered
  • Understand the magnitude of Migraine population by its prevalent cases
  • Understand the magnitude of Migraine population by its clinical manifestation of diagnosed cases of Chronic and Episodic Migraine 
  • The Migraine epidemiology report and model was written and developed by Masters and PhD level epidemiologists
  • The Migraine Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Report Introduction

3. Migraine Market Overview at a Glance

3.1. Market Share (%) Distribution of Migraine in 2019

3.2. Market Share (%) Distribution of Migraine in 2032

4. Executive Summary of Migraine

5. Disease Background and Overview

5.1. Introduction

5.2. Symptoms

5.3. Cause

5.4. Risk Factors

5.5. Types of Migraine

5.6. Migraine With/Without Aura

5.7. Pathophysiology

5.8. Diagnosis

6. Treatment

6.1. American Headache Society Guidelines for Migraine

6.2. Guideline by Chronic Headache Clinical Practice Development Committee of Japan

6.3. Nice Guidelines for Migraine Management

7. Epidemiology and Patient Population

7.1. Key Findings

7.2. 7MM Total Prevalent Patient Population of Migraine

7.3. Epidemiology of Migraine

7.4. The United States

7.4.1. Prevalence of Migraine in the United States

7.4.2. Prevalent Cases of Migraine by severity in the United States

7.4.3. Gender-specific Prevalence of Migraine in the United States

7.4.4. Diagnosed Cases of Episodic and Chronic Migraine in the United States (000’s)

7.5. The EU-5

7.5.1. Prevalence of Migraine in the EU5

7.5.2. Prevalent Cases of Migraine by severity in the EU-5

7.5.3. Gender-specific Prevalence of Migraine in the EU5

7.5.4. Diagnosed Cases of Episodic and Chronic Migraine in the EU5

7.6. Japan

7.6.1. Prevalence of Migraine in Japan

7.6.2. Prevalent Cases of Migraine based on Severity in Japan

7.6.3. Gender-specific Prevalence of Migraine in Japan (in 000’s)

7.6.4. Diagnosed Cases of Episodic and Chronic Migraine in Japan

8. Patient Journey

9. Patient Journey

10. KOL Views

11. Unmet Needs

12. SWOT Analysis

13. Appendix

13.1. Bibliography

13.2. Report Methodology

14. DelveInsight Capabilities

15. Disclaimer

16. About DelveInsight

List of Tables

Table 1: Summary of Migraine, Market, Epidemiology, and Key Events (2019–2032)

Table 2: Patient Characteristics of EM vs. CM

Table 3: ICHD-3 (Beta) Criteria for Migraine With Aura

Table 4: ICHD-3 (Beta) Criteria for Migraine Without Aura

Table 5: ICHD-3 (Beta) Diagnostic Criteria for CM

Table 6: Differential Diagnosis of Primary Chronic Headache of Long Duration

Table 7: Total Prevalent Patient Population of Migraine in 7MM (2019–2032)

Table 8: Prevalence of Migraine in the United States (2019–2032)

Table 9: Prevalent Cases of Migraine based on severity in the United States (2019–2032)

Table 10: Gender-specific Prevalence of Migraine in the United States (2019–2032)

Table 11: Diagnosed Cases of Episodic and Chronic Migraine in the United States (2019–2032)

Table 12: Prevalence of Migraine in the EU5 (2019–2032)

Table 13: Prevalent Cases of Migraine by severity in the EU-5 (2019–2032)

Table 14: Gender-specific Prevalence of Migraine in the EU5 (2019–2032)

Table 15: Diagnosed Cases of Episodic and Chronic Migraine in the EU5 (2019–2032)

Table 16: Prevalence of Migraine in Japan thousands (2019–2032)

Table 17: Prevalent Cases of Migraine by severity in Japan (2019–2032)

Table 18: Gender-specific Prevalence of Migraine in Japan (2019–2032)

Table 19: Diagnosed Cases of Episodic and Chronic Migraine in Japan (2019–2032)

List of Figures

Figure 1: Multiple factors contribute to migraine chronification

Figure 2: Algorithmic approach to diagnosing migraine

Figure 3: Multiple factors contribute to migraine chronification

Figure 4: Total Prevalent Population of Migraine in 7MM (2019–2032)

Figure 5: Prevalence of Migraine in the United States (2019–2032)

Figure 6: Prevalent Cases of Migraine by severity in the United States (2019–2032)

Figure 7: Gender-specific Prevalence of Migraine in the United States (2019–2032)

Figure 8: Diagnosed Cases of Episodic and Chronic Migraine in the United States (2019–2032)

Figure 9: Prevalence of Migraine in the EU5 (2019–2032)

Figure 10: Prevalent Cases of Migraine by severity in the EU-5 (2019–2032)

Figure 11: Gender-specific Prevalence of Migraine in the EU5 (2019–2032)

Figure 12: Diagnosed Cases of Episodic and Chronic Migraine in the EU5 (2019–2032)

Figure 13: Prevalence of Migraine in Japan (2019–2032)

Figure 14: Prevalent Cases of Migraine by severity in Japan (2019–2032)

Figure 15: Gender-specific Prevalence of Migraine in Japan (2019–2032)

Figure 16: Diagnosed Cases of Episodic and Chronic Migraine in Japan (2019–2032)

Forward to Friend

Need A Quote